Awardee OrganizationUNIVERSITY OF CALIFORNIA LOS ANGELES
Description
Abstract Text
The Gene Regulation Program Area is composed of 21 members, spanning 8 Departments within UCLA. In
;he past competing cycle, investigators from this Program authored 374 publications, of which 94 (25%) were
nter-programmatic and 15 (4%) intra-programmatic. 155 (41%) were placed in high-impact journals. 15
members of this Program Area used 8 out of the 8 Shared Resources that are currently funded by the JCCC.
During the current funding year, peer-reviewed funding totaled $12.2 million in total costs, including $1.6
million from the National Cancer Institute. As with other Program Areas, JCCC fosters a number of interactive
activities and many of the Shared Resources that support investigators in the GR Program Area. During the
current grant cycle, funds from the JCCC in the form of CCSG Developmental Funds, institutional support and
philanthropic gifts to the GR Program Area total $832,185. These funds supported Interdisciplinary Grants,
Seed Grants, recruitment/retention, Program Area Leadership support, funding for the use of emerging Shared
Resources and trainees. Twelve of the Program Area Members were the recipients of JCCC support.
The Gene Regulation Program Area is completing its first full CCSG cycle. The initial goal of the Program
Area was to bring together the strong existing group of gene regulation researchers at UCLA and to develop a
collective interest in the application of gene regulation studies to problems of cancer origin, development, and
therapy. The original group of 12 has grown to 21 members, in large part by recruitment of a group of
extraordinary young investigators as Assistant Professors. Substantial investment by the JCCC, the DGSoM,
and the College of Letters and Science has benefited this Program Area enormously. During the current
CCSG cycle, we have focused on four major objectives: (1) to promote among our members the study of
fundamental mechanisms of gene regulation, using appropriate model organisms, mammalian cells, and
animal models; (2) to study the molecular/transcriptional mechanisms that mediate cell differentiation,
nflammation and viral latency and investigate how aberrations in these processes affect cancer initiation and
progression; (3) to serve as a resource for the other Program Areas in the JCCC in the use of gene regulation
concepts and methodologies to advance their research problems; and (4) to promote the translation of existing
knowledge and new discoveries into translational and clinical applications. Interactions among members are
fostered by a monthly meeting, a weekly journal club, and a seminar series that brings "leaders in the field" to
UCLA.
Public Health Relevance Statement
Data not available.
NIH Spending Category
BiotechnologyCancer
Project Terms
AffectAnimal ModelAreaCancer Center Support GrantCell Differentiation processDevelopmentDiagnosisFosteringFundingGene Expression RegulationGiftsGoalsGrantInflammationInvestmentsJonsson Comprehensive Cancer Center of University of California Los AngelesJournalsKnowledgeLeadershipLettersMalignant NeoplasmsMammalian CellMediatingMethodologyMolecularNational Cancer InstitutePeer ReviewPhysiological ProcessesProcessPublicationsRegulationResearchResearch PersonnelResource SharingResourcesScienceSeedsSeriesTranslationsVirus Latencycancer initiationcancer therapyclinical applicationcollegecostexpectationinsightinterestmeetingsmembernovel strategiesprofessorprogramstherapy development
No Sub Projects information available for 2P30CA016042-34 5610
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 2P30CA016042-34 5610
Patents
No Patents information available for 2P30CA016042-34 5610
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 2P30CA016042-34 5610
Clinical Studies
No Clinical Studies information available for 2P30CA016042-34 5610
News and More
Related News Releases
No news release information available for 2P30CA016042-34 5610
History
No Historical information available for 2P30CA016042-34 5610
Similar Projects
No Similar Projects information available for 2P30CA016042-34 5610